Anaphylaxis in Mastocytosis

Escribano, Luís; Órfão, Alberto

doi:10.1007/978-1-60327-951-2_16

Cited by 7 publications

(8 citation statements)

References 105 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among DHRs, anaphylaxis is of greater concern since it is life-threatening. The prevalence of both atopy [ 15 , 16 , 17 ] or IgE-mediated diseases [ 3 ] in the general population is similar to that of patients with mastocytosis. Even if the high number of MCs as well as the greater releasability of MCs may increase the risk for anaphylaxis [ 16 , 18 ], the rate of anaphylaxis in children (4%) is much lower than in adults with mastocytosis (49%) [ 19 , 20 ], but it is elevated compared to that in normal children.…”

Section: Findings In Anaphylactic Reactionsmentioning

confidence: 99%

“…Therefore, patients with mastocytosis should be provided with clear recommendations on which drugs should be allowed and which ones should be excluded. Physical stimuli (i.e., heat, cold, quick variations of temperature and rubbing of skin lesions), stress and anxiety can activate MCs [ 3 ], misleading the diagnosis in case of concomitant administration of drugs.…”

Section: Drug Hypersensitivity Reactions In Mastocytosismentioning

confidence: 99%

“…Mastocytosis is a disease characterized by growth and build-up of neoplastic mast cells (MCs) in different organ systems. Symptoms are induced by released MC mediators (i.e., skin itching, hives, angioedema, pain in the abdomen and anaphylaxis), or by infiltration of MCs within affected organs, such as skin, bone marrow, gastrointestinal tract, liver and spleen [ 1 , 2 , 3 ]. The prevalence of mastocytosis has been reported to be 0.9–1.3 per 10,000 inhabitants [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Drugs and Vaccines Hypersensitivity in Children with Mastocytosis

Mori

Crisafulli

Bianchi

et al. 2022

JCM

View full text Add to dashboard Cite

Mastocytosis, a heterogeneous mastcell disease, include three different entities: cutaneous mastocytosis, systemic mastocytosis (SM) and mast-cell sarcoma. Tryptase levels can differentiate cutaneous mastocytosis from SM. In mastocytosis, quick onset drug hypersensitivity reactions (DHRs) that are facilitated by mastcell mediators, are investigated in adults. Due to the limited number of children with mastcell disease and increased serum tryptase levels, the role of drugs in this age group is less studied. In this review, we critically assessed relevant papers related with immediate DHRs in children with mastocytosis and discuss practical issues of the management. In childhood mastocytosis, anaphylaxis is frequently idiopathic, and elevated level of basal tryptase, and high burden of disease may increase the risk. Among drugs, antibiotics, NSAIDs and opioids can potentially induce anaphylaxis, anyway avoidance should be recommended only in case of previous reactions. Moreover, vaccinations are not contraindicated in patients with mastocytosis. The risk of severe systemic reactions after drugs intake seems to be extremely low and in general lower in children than in adults. Anyway, studies on this topic especially focusing on children, are missing to state final recommendations.

show abstract

Section: Findings In Anaphylactic Reactionsmentioning

confidence: 99%

Section: Drug Hypersensitivity Reactions In Mastocytosismentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Drugs and Vaccines Hypersensitivity in Children with Mastocytosis

Mori

Crisafulli

Bianchi

et al. 2022

JCM

View full text Add to dashboard Cite

show abstract

“…Nevertheless, the prevalence of anaphylaxis has been reported to be up to 100 times more frequent among patients with SM vs. general population ( 33 , 34 ) with an overall frequency that ranges from 22 and 49% in adults ( 32 , 35 , 36 ) and between 6 and 9% in children ( 32 , 35 ). Furthermore, it seems to occur more often in patients with clonal MC disease without cutaneous involvement ( 24 , 37 ). In fact, anaphylaxis is commonly the presenting symptom in patients with ISMs− and MMAS ( 18 , 34 , 38 ).…”

Section: Epidemiology Triggers and Risk Factors Of Anaphylaxis In Cmentioning

confidence: 99%

Insights in Anaphylaxis and Clonal Mast Cell Disorders

González-de-Olano

Álvarez‐Twose

2017

Front. Immunol.

View full text Add to dashboard Cite

The prevalence of anaphylaxis among patients with clonal mast cell disorders (MCD) is clearly higher comparing to the general population. Due to a lower frequency of symptoms outside of acute episodes, clonal MCD in the absence of skin lesions might sometimes be difficult to identify which may lead to underdiagnosis, and anaphylaxis is commonly the presenting symptom in these patients. Although the release of mast cell (MC) mediators upon MC activation might present with a wide variety of symptoms, particular clinical features typically characterize MC mediator release episodes in patients with clonal MCD without skin involvement. Final diagnosis requires a bone marrow study, and it is recommended that this should be done in reference centers. In this article, we address the main triggers for anaphylaxis, risk factors, clinical presentation, diagnosis, and management of patients with MC activation syndromes (MCASs), with special emphasis on clonal MCAS [systemic mastocytosis and mono(clonal) MC activations syndromes].

show abstract

“… a Frequency of mast cell (MC) mediator-related symptoms of 2% in pediatric mastocytosis and 14% in adult mastocytosis 83 b Frequency of MC mediator-related symptoms and anaphylaxis of 2% and 0.4% in adult mastocytosis, respectively 84 ; 4% of MC mediator-related symptoms and 0–2% of anaphylaxis in pediatric mastocytosis 84– 86 c Prophylactic anti-mediator therapy is recommended in all cases 87 d Infrequent, based on one case report (Javed Sheik, Beth Israel Hospital, Harvard Medical School, personal communication, September 2002) e Infrequent, based on case report 88 f Infrequent, based on case reports 89, 90 GI, gastrointestinal; IgE, immunoglobulin E; NSAID, non-steroidal anti-inflammatory drug. Adapted with permission from Ergon 91 .…”

Section: Clinical Features Of Patients With Primary Mast Cell Activatmentioning

confidence: 99%

Advances in the understanding and clinical management of mastocytosis and clonal mast cell activation syndromes

et al. 2016

Self Cite

View full text Add to dashboard Cite

Clonal mast cell activation syndromes and indolent systemic mastocytosis without skin involvement are two emerging entities that sometimes might be clinically difficult to distinguish, and they involve a great challenge for the physician from both a diagnostic and a therapeutic point of view. Furthermore, final diagnosis of both entities requires a bone marrow study; it is recommended that this be done in reference centers. In this article, we address the current consensus and guidelines for the suspicion, diagnosis, classification, treatment, and management of these two entities.

show abstract

Anaphylaxis in Mastocytosis

Cited by 7 publications

References 105 publications

Drugs and Vaccines Hypersensitivity in Children with Mastocytosis

Drugs and Vaccines Hypersensitivity in Children with Mastocytosis

Insights in Anaphylaxis and Clonal Mast Cell Disorders

Advances in the understanding and clinical management of mastocytosis and clonal mast cell activation syndromes

Contact Info

Product

Resources

About